MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Both nations deepen cooperation in health innovation, AI-driven healthcare, biomedical research, data sharing, and life sciences to accelerate next-generation healthcare solutions
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
The decision was driven by results from the Phase III CAPItello-281 trial,
Approval is based on results from the phase 3 OASIS 4 clinical trial
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Company experts to participate in eight sessions covering AI-powered clinical development, regulatory innovation, oncology research, and patient engagement
The milestone, announced from Wilmington, Delaware, is powered through additional Renewable Energy Certificates (RECs) and backed by US-sourced renewable generation
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
